Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
Moderna pushes the boundaries of mRNA therapy into rare genetic diseases, aiming for transformative treatments.
Manufacturing breakthroughs are set to transform cell therapy production, paving the way for faster trials and wider patient …
AI-driven drug discovery is accelerating innovation and transforming biopharma R&D.
Australia’s National Genomic Registry is connecting patients, clinicians, and researchers to transform rare disease care in real time.
New device approval and robust oncology funding highlight ongoing biopharma momentum in cancer therapies.
Already a subscriber? Log in